Skip to content
User

Parnassus Investments

Parnassus Endeavor Fund

Parnassus Endeavor Fund AstraZeneca PLC stake

total: 118

Parnassus Endeavor Fund AZN-OLD trades

Total transactions:
6
New positions:
1
Sold out:
1
Added:
3
Reduced:
1
Held since:
2024 Q4
Held for:
5 quarters
Latest activity:
2026 Q1
According to 2026 Q2 report, Parnassus Endeavor Fund doesn't hold any AstraZeneca PLC (AZN-OLD) shares. To date, the estimated cost basis is nearly $66.03 for "buy" trades and estimated average "sell" price is $91.93. Parnassus Endeavor Fund first purchased AZN-OLD in 2024 Q4, initially acquiring about 1.18M shares. Since the initial investment in AstraZeneca PLC (AZN-OLD), Parnassus Endeavor Fund has made 5 more transactions.

When did Parnassus Endeavor Fund sell AstraZeneca PLC (AZN-OLD)?

Parnassus Endeavor Fund sold off the entire AstraZeneca PLC (AZN-OLD) position in 2026 Q1.

When did Parnassus Endeavor Fund buy AstraZeneca PLC (AZN-OLD)?

Parnassus Endeavor Fund first invested in AstraZeneca PLC (AZN-OLD) in 2024 Q4 at the reported quarter-end price of $65.52 per share.

What's the cost basis of Parnassus Endeavor Fund's AZN-OLD stake?

The estimated cost basis for AstraZeneca PLC (AZN-OLD) stake is around $66.03 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$66.03
Weighted AVG sell price:
$91.93

Parnassus Endeavor Fund's historical trades in AstraZeneca PLC

6 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q1
0.00%
0
$91.93
-100% (-1,227,628)
-2.37%
2025 Q4
2.37%
1,227,628
$91.93
$112,855,842
-4.43% (-56,963)
-0.11%
2025 Q3
2.09%
1,284,591
$76.72
$98,553,822
+0.39% (+5,030)
+0.01%
2025 Q2
1.97%
1,279,561
$69.88
$89,415,723
+4.77% (+58,277)
+0.09%
2025 Q1
2.00%
1,221,284
$73.50
$89,764,374
+3.65% (+42,961)
+0.07%
2024 Q4
1.60%
1,178,323
$65.52
$77,203,723
new
+1.6%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.